The last few years have seen significant developments in the field of Advanced Therapy Medicinal Products (ATMPs), leading to the innovation of next-generation therapeutics for previously untreatable and often life-limiting illnesses, ranging from genetic disorders to cancer.
However, the lack of single, all-purpose analytical solutions, combined with the rapidly evolving regulatory environment, can make the development and manufacturing of these novel therapies challenging.
To support the delivery of innovative cell and gene therapies, RSSL offers integrated analytical services that can support early-stage development through to IND applications, commercial manufacturing and product release.
